New findings and treatment considerations for using glucagon-like peptide-1 drugs in older people with HIV

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being increasingly considered for people with HIV due to their effects on cardiometabolic health.

• GLP-1RAs may have beneficial effects on weight management and glycemic control.
• There is emerging evidence suggesting safety in the use of GLP-1RAs among people with HIV.
• Implementation considerations for GLP-1RAs in this population are being evaluated to address unique health challenges.
• People with HIV often face heightened risks for cardiometabolic diseases, making effective treatment options critical.

Simplified